Made Smarter Innovation - Digital Medicines Manufacturing Research Centre
Lead Research Organisation:
University of Strathclyde
Department Name: Inst of Pharmacy and Biomedical Sci
Abstract
Powered by data, Industrial Digital Technologies (IDTs) such as artificial intelligence and autonomous robots, can be used to improve all aspects of manufacturing and supply of products along supply chains to the customer. Many companies are embracing these technologies but uptake within the pharmaceutical sector has not been as rapid. The Medicines Made Smarter Data Centre (MMSDC) looks to address the key challenges which are slowing digitalisation, and adoption of IDTs that can transform processes to deliver medicines tailored to patient needs.
Work will be carried out across five integrated platforms designed by academic and industrial researcher teams. These are: 1) The Data Platform, 2) Autonomous MicroScale Manufacturing Platform, 3) Digital Quality Control Platform, 4) Adaptive Digital Supply Platform, and 5) The MMSDC Network & Skills Platform.
Platform 1 addresses one of the sector's core digitalisation challenges - a lack of large data sets and ways to access such data. The MMSDC data platform will store and analyse data from across the MMSDC project, making it accessible, searchable and reusable for the medicines manufacturing community. New approaches for ensuring consistently high-quality data, such as good practice guides and standards, will be developed alongside data science activities which will identify what the most important data are and how best to use them with IDTs in practice.
Platform 2 will accelerate development of medicine products and manufacturing processes by creating agile, small-scale production facilities that rapidly generate large data sets and drive research. Robotic technologies will be assembled to create a unique small-scale medicine manufacturing and testing system to select drug formulations and processes to produce stable products with the desired in-vitro performance. Integrating several IDTs will accelerate drug product manufacture, significantly reducing experiments and dramatically reducing development time, raw materials and associated costs.
Platform 3 focusses on the digitalisation of Quality Control (QC) aspects of medicines development which is important for ensuring a medicine's compliance with regulatory standards and patient safety requirements. Currently, QC checks are carried out after a process has been completed possibly spotting problems after they have occurred. This approach is inefficient, fragmented, costly (>20% of total production costs) and time consuming. The digital QC platform will research how to transform QC by utilising rich data from IDTs to confirm in real time product and process compliance.
Platform 4 will generate new understanding on future supply chain needs of medicines to support adoption of adaptive digital supply chains for patient-centric supply. IDTs make smaller scale, autonomous factory concepts viable that support more flexible and distributed manufacture and supply. Supply flexibility and agility extends to scale, product variety, and shorter lead-times (from months to days) offering a responsive patient-centric or rapid replenishment operating model. Finally, technology developments closer to the patient, such as diagnostics provide visibility on patient specific needs.
Platform 5 will establish the MMSDC Network & Skills Platform. This Network will lead engagement and collaboration across key stakeholder groups involved in medicines manufacturing and investments. The Network brings together the IDT-using community and other relevant academic and industrial groups to share developments across pharmaceuticals and broader digital manufacturing sectors ensuring cross-sector diffusion of MMSDC research. Existing strategic networks will support MMSDC and act as gateways for IDT dissemination and uptake. The lack of appropriate skills in the workforce has been highlighted as a key barrier to IDT adoption. An MMSDC priority is to identify skills needs and with partners develop and deliver training to over 100 users
Work will be carried out across five integrated platforms designed by academic and industrial researcher teams. These are: 1) The Data Platform, 2) Autonomous MicroScale Manufacturing Platform, 3) Digital Quality Control Platform, 4) Adaptive Digital Supply Platform, and 5) The MMSDC Network & Skills Platform.
Platform 1 addresses one of the sector's core digitalisation challenges - a lack of large data sets and ways to access such data. The MMSDC data platform will store and analyse data from across the MMSDC project, making it accessible, searchable and reusable for the medicines manufacturing community. New approaches for ensuring consistently high-quality data, such as good practice guides and standards, will be developed alongside data science activities which will identify what the most important data are and how best to use them with IDTs in practice.
Platform 2 will accelerate development of medicine products and manufacturing processes by creating agile, small-scale production facilities that rapidly generate large data sets and drive research. Robotic technologies will be assembled to create a unique small-scale medicine manufacturing and testing system to select drug formulations and processes to produce stable products with the desired in-vitro performance. Integrating several IDTs will accelerate drug product manufacture, significantly reducing experiments and dramatically reducing development time, raw materials and associated costs.
Platform 3 focusses on the digitalisation of Quality Control (QC) aspects of medicines development which is important for ensuring a medicine's compliance with regulatory standards and patient safety requirements. Currently, QC checks are carried out after a process has been completed possibly spotting problems after they have occurred. This approach is inefficient, fragmented, costly (>20% of total production costs) and time consuming. The digital QC platform will research how to transform QC by utilising rich data from IDTs to confirm in real time product and process compliance.
Platform 4 will generate new understanding on future supply chain needs of medicines to support adoption of adaptive digital supply chains for patient-centric supply. IDTs make smaller scale, autonomous factory concepts viable that support more flexible and distributed manufacture and supply. Supply flexibility and agility extends to scale, product variety, and shorter lead-times (from months to days) offering a responsive patient-centric or rapid replenishment operating model. Finally, technology developments closer to the patient, such as diagnostics provide visibility on patient specific needs.
Platform 5 will establish the MMSDC Network & Skills Platform. This Network will lead engagement and collaboration across key stakeholder groups involved in medicines manufacturing and investments. The Network brings together the IDT-using community and other relevant academic and industrial groups to share developments across pharmaceuticals and broader digital manufacturing sectors ensuring cross-sector diffusion of MMSDC research. Existing strategic networks will support MMSDC and act as gateways for IDT dissemination and uptake. The lack of appropriate skills in the workforce has been highlighted as a key barrier to IDT adoption. An MMSDC priority is to identify skills needs and with partners develop and deliver training to over 100 users
Organisations
- University of Strathclyde (Lead Research Organisation)
- Centre for Process Innovation (CPI) (Collaboration)
- LOUGHBOROUGH UNIVERSITY (Collaboration)
- UNIVERSITY OF STRATHCLYDE (Collaboration)
- Altair Engineering (United Kingdom) (Collaboration)
- NVIDIA (Collaboration)
- Chiesi (Collaboration)
- KUKA Robotics (Collaboration)
- Siemens (United Kingdom) (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- Cancer Research UK (Collaboration)
- Applied Materials (Collaboration)
- Eli Lilly & Company Ltd (Collaboration)
- BDD Pharma Ltd (Collaboration)
- National Physical Laboratory (Collaboration)
- UCB SA (Collaboration)
- Medicines and Healthcare Regulatory Agency (Collaboration)
- Smith and Nephew (Collaboration)
- Malvern Panalytical (Collaboration)
- AstraZeneca (Collaboration)
- Pfizer Ltd (Collaboration)
- Roche Pharmaceuticals (Collaboration)
- Cambridge Crystallographic Data Centre (Collaboration, Project Partner)
- GlaxoSmithKline (GSK) (Collaboration)
- INNOVATE UK (Collaboration)
- UNIVERSITY OF NOTTINGHAM (Collaboration)
- Takeda Pharmaceutical Company (Collaboration)
- Henry Royce Institute (Collaboration)
- MG2 S.r.l. (Project Partner)
- Centre for Process Innovation (Project Partner)
- Calderdale & Huddersfield NHS Foun Trust (Project Partner)
- NVIDIA Limited (UK) (Project Partner)
- Connected Everything Network+ (II) (Project Partner)
- EPSRC Future Manufact Hub Target Health (Project Partner)
- Altair Engineering (United Kingdom) (Project Partner)
- Perceptive Engineering (United Kingdom) (Project Partner)
- TÜV SÜD (United Kingdom) (Project Partner)
- Dietrich Engineering Consultants S.A. (Project Partner)
- Fette Compacting (Project Partner)
- MEDELPHARM (Project Partner)
- Knowledge Transfer Network KTN (Project Partner)
- Process Systems Enterprise (United Kingdom) (Project Partner)
- CPACT (Project Partner)
- Blaze Metrics, LLC. (Project Partner)
- KUKA (United Kingdom) (Project Partner)
- GSK (UK) (Project Partner)
- Malvern Panalytical Ltd (Project Partner)
- Henry Royce Institute (Project Partner)
- National Physical Laboratory (Project Partner)
- AstraZeneca (United Kingdom) (Project Partner)
- Chiesi Pharmaceuticals (Project Partner)
- UCB Pharma (Belgium) (Project Partner)
- Bio-Images Drug Delivery (United Kingdom) (Project Partner)
- Smith & Nephew plc (UK) (Project Partner)
Publications
Anandan P
(2022)
32nd European Symposium on Computer Aided Process Engineering
Bouchkira I
(2022)
32nd European Symposium on Computer Aided Process Engineering
Bouchkira I
(2023)
33rd European Symposium on Computer Aided Process Engineering
Bouchkira I
(2023)
33rd European Symposium on Computer Aided Process Engineering
Poole A
(2021)
A Novel Complete-Surface-Finding Algorithm for Online Surface Scanning with Limited View Sensors.
in Sensors (Basel, Switzerland)
Joglekar N
(2022)
Configuration of digital and physical infrastructure platforms: Private and public perspectives
in Production and Operations Management
Liu J
(2024)
Single and Multiobjective Shutdown Optimization of a Multistage Continuous Crystallizer
in Industrial & Engineering Chemistry Research
Wilkinson M
(2023)
Predicting pharmaceutical powder flow from microscopy images using deep learning
in Digital Discovery
Liu J
(2022)
Optimal start-up strategies of a combined cooling and antisolvent multistage continuous crystallization process
in Computers & Chemical Engineering
| Title | DM2 project overview |
| Description | The video provides an overview of the project objectives, partners, and deliverables. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2023 |
| Impact | Created great project summary that was displayed during the 1st generation demonstrators (CMAC Open days-2023) |
| URL | https://cmac.ac.uk/dm2-home |
| Title | Digital Medicines Manufacturing (DM²) |
| Description | An overview of the DM2 centre |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2022 |
| Impact | Increased the awareness regarding the DM2 project |
| URL | https://www.youtube.com/watch?v=0vNqEm4aAp0 |
| Title | Platform 1 summary (illustrative video) |
| Description | The video provides an overview of platform 1 objectives and deliverables. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2023 |
| Impact | Excellent platform 1 summary that was displayed during the 1st generation demonstrators (CMAC Open days-2023) |
| URL | https://cmac.ac.uk/dm2-platform-1-1 |
| Title | Platform 2 summary (illustrative video) |
| Description | The video provides an overview of platform 2 objectives and deliverables. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2023 |
| Impact | Excellent platform 2 summary that was displayed during the 1st generation demonstrators (CMAC Open days-2023) |
| URL | https://cmac.ac.uk/dm2-platform-2-1 |
| Title | Platform 3 summary (illustrative video) |
| Description | The video provides an overview of platform 3 objectives and deliverables. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2023 |
| Impact | Excellent platform 1 summary that was displayed during the 1st generation demonstrators (CMAC Open days-2023) |
| URL | https://cmac.ac.uk/dm2-platform-3-1 |
| Title | Platform 4 summary (illustrative video) |
| Description | The video provides an overview of platform 4 objectives and deliverables. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2023 |
| Impact | Excellent platform 4 summary that was displayed during the 1st generation demonstrators (CMAC Open days-2023) |
| URL | https://cmac.ac.uk/dm2-platform-4-1 |
| Title | Platform 5 summary (illustrative video) |
| Description | The video provides an overview of platform 5 objectives and deliverables. |
| Type Of Art | Film/Video/Animation |
| Year Produced | 2023 |
| Impact | Excellent platform 5 summary that was displayed during the 1st generation demonstrators (CMAC Open days-2023) |
| URL | https://cmac.ac.uk/dm2-platform-5-1 |
| Description | The DM² recognises that data and industrial digital technologies (IDTs) are essential for the development of integrated digital solutions that will hugely improve the manufacturing of medicines. The project is generally progressing very well through the following activities: • Research: The project is developing as planned, and research activities continuing to achieve the objectives of the five platforms: Platform 1: The team have developed ontology mechanisms to extract biomedical relations from text and Extract, Transform and Load (ETL) tools to simplify data acquisition, databasing and visualisation. Platform 1 has also been involved in the creation of an automated sessile drop experiment for the real-time testing of tablet disintegration properties. This is an integral part of the testing mechanisms being integrated into the Platform 2 automated microscale tabletting and testing workflow. Also, first version of dataset for training MediMegatron has been assembled, trained, and completed initial benchmarking against other models. Platform 2: The team has been working on an autonomous microscale production facility, utilising AI, robotics and computational modelling. The team have created a small-scale manufacturing set-up integrating several technologies and instruments to make and test individual medicine tablets. This has the capacity to run independently on user-defined and/or self-driven experiments. Platform 2 is also working with platform 3 on the process of developing a first prototype for the automated slug analysis system for capsule manufacturing. Platform 3: The platform 3 team has created a toolbox named ESTAN to get the most out of data and models, increase the reliability of model-based design of experiments and realise cost and time saving benefits. For similar reasons, the team is also running an investigation into quality control mechanisms for a low-dose capsule filling process, using Discrete Element Methods (DEM). Exploring how planning and scheduling of clinical trials can be informed by data generated through this digital quality control research has also been initiated by the team. Platform 4: A number of use cases have been initiated with project partners in the healthcare sector. The first of these cases is centred on digital platform developments, connecting pharmaceutical and medical device manufacturing operations to downstream healthcare product procurement systems to enhance availability. Another case seeks to make clinical trials more resilient and effective by leveraging extensive analysis of clinical trial supply chain data, and investigating digital interventions to prevent stock-out events. Thirdly, the team is researching production and logistics synchronisation for smart pharmaceutical manufacturing to streamline processes, enhance efficiency, improve stocks, and reduce waiting times and operational costs. Platform 5: The team leads stakeholder engagement and collaboration, and has been running a schedule of activities such as webinars, workshops and conference events to maintain and grow an informed, diverse network of medicines manufacturing stakeholders. The platform 5 team established the SkillsFactory platform that will offer excellent training courses on various IDTs. In addition, the team collaborated with Glasgow School of Art to develop augmented reality (AR) case studies for skills development and developed an AR-based model of the platform 2 laboratory. • Industry participation: 31 partners are engaging with all the five platforms. In addition, growth contributions from existing and new partners are being identified and progressed. • KPIs: the project is on track to achieve the KPIs targets, which include publications (14 published and many in progress), demonstrators (13 delivered as part of the 1st generation demonstrators showcase), use cases (one completed and others progressing), reducing waste (witnessed through the automated system), people training (478 people trained through workshops, summer schools, and webinars), and co-investment (~£2 million by the end of 2023). • First generation DM2 demonstrators: The DM² team has worked hard over five integrated delivery platforms to achieve their goals and demonstrated their achievements. To mark the project's mid-point, the team shared their progress at a showcase during CMAC Open Days (November 2023). Following the successful delivery of the 1st generation demonstrators, the entire DM2 team is currently working to achieve the 2nd generation demonstrators that will be showcased at the end of the project in March 2025. |
| Exploitation Route | The outcomes of this award could be taken forward through partnerships with industry, and follow-on awards and projects to further progress the deliverables. These outcomes will benefit the academic community, pharma industry and tech providers, regulatory authorities, and the entire society. |
| Sectors | Chemicals Digital/Communication/Information Technologies (including Software) Education Healthcare Manufacturing including Industrial Biotechology Pharmaceuticals and Medical Biotechnology |
| Description | Medicines manufacturing contribute hugely to the UK economy. However, different challenges hinder the progress of this sector including high competitions (raw materials, supply chain, and prices), elevated cost, long development time, limited adoption of digital technologies, and low environmental sustainability of this sector. Therefore, the DM2 was established to decrease waste, boost efficiency, foster a future-ready workforce, and enhance the responsiveness of the medicines manufacturing industry for faster, sustainable delivery of medicines to patients. Through collaboration with industry and academic partners, DM² co-creates and co-delivers innovations aimed at improving patient outcomes and ensuring the industry's readiness for the future. The impact of each of the platforms are as follows: Platform 1: The team's research focuses on data organisation, aiming for data to be Findable, Accessible, Interoperable, and Reusable (FAIR) to enhance its usability in manufacturing. Activities of platform 1 will ensure that data is created, gathered, and utilised in an efficient way through various Data Factories to be used efficiently to train the AI models and guide the manufacturing process within platform 2. Platform 2: The integrated microscale manufacturing system is the core of the DM2 project. Driven and optimised by computational models and machine learning, it helps identify the best formulation and process conditions to maximise drug product quality attributes, reduce waste and cut development time. This is a crucial finding that will help accelerating the medicine manufacturing process and improving the manufacturing environmental impact. Platform 3: The team's research is driving digitalisation of quality control processes by developing digital design tools that streamline medicines manufacturing. These are focused on ensuring safe medicine release by creating data-driven, integrated safety and compliance checks in real-time. The platform 3 tools will also accelerate the manufacturing process without compromising the importance of developing high quality medicines that can be approved by regulatory authorities. Platform 4: The team is investigating the impact of digital interventions on creating an adaptive supply network that responds to changing materials supply and healthcare provider needs. The three case studies demonstrate the importance of this platform, which will create a demand signal, for example from a clinical trial, that will be passed to platforms 1-3 to propose a formulation, manufacture the required tablets, and examine the quality of the manufactured tablets prior to releasing them for delivery. Platform 5: Engagement is critical to building trust in new Industrial Digital Technologies (IDTs) and nurturing an appetite for their implementation and the beneficial changes they will bring. Critical to this is a confident and sufficiently skilled workforce, ready to implement and work alongside new IDTs. The SkillsFactory, integrating immersive tech like Augmented Reality and other training courses, will prepare the workforce for the digital era. The project outcomes will collectively improve the medicine manufacturing process, collaboration with the industry to achieve an economic growth, train of the future workforce to enhance employability and societal development, and sustain the UK position as a leading nation in innovation and medicines manufacturing. The DM2 outputs also helped to advance pathways for translation, and fed into the development of various funding applications including UKRPIF partnership, EPSRC CDT in Cyber-Physical Systems for Medicine Development and Manufacturing (CEDAR), and EPSRC Manufacturing Hub for Sustainable Futures Call (MediForge). |
| Sector | Chemicals,Education,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
| Impact Types | Cultural Societal Economic Policy & public services |
| Description | Membership of the Skills subgroup of Medicines Manufacturing Industry Partnership (MMIP) |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | MMIP has identified six objectives for medicines manufacturing skills in the UK: 1: Promote the Medicines Manufacturing Industry and careers within it 2: Create apprenticeships standards to enable companies to use the Apprenticeship Levy 3: Share and promote good practice for training and skills development 4: Address the low level of practical skills in graduates and other new-starters 5: Address the issues arising from there being relatively small national cohorts for education and training in a number of critical skills areas 6: As part of the ATMP Taskforce recommendations, deliver an End to End Talent Management Plan for the sector and establish a Skills and Training Academy for the UK |
| URL | https://www.abpi.org.uk/r-d-manufacturing/medicines-manufacturing-industry-partnership-mmip/ |
| Description | CCDC Engagement Grant Programme |
| Amount | £1,500 (GBP) |
| Organisation | Cambridge Crystallographic Data Centre |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2023 |
| End | 07/2023 |
| Description | Dialling up performance for on demand manufacturing |
| Amount | £5,865,535 (GBP) |
| Funding ID | EP/W017032/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2022 |
| End | 09/2027 |
| Description | StrathWide 2023 Funding Call, Project Title: Deep learning characterisation of nano-in-micro particles for nose-to-brain drug delivery. DM2 researcher (Dr Mohammad Salehian) |
| Amount | £5,000 (GBP) |
| Funding ID | StrathWide 2023 Funding Call, University of Strathclyde |
| Organisation | University of Strathclyde |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2023 |
| End | 08/2024 |
| Description | StrathWide 2023 Funding Call, Project Title: From Pixels to Particles: A Computational Toolbox for Predicting Pharmaceutical Powder Characteristics. DM2 Team (Dr Mohammad Salehian, Dr John Armstrong, and Dr Christopher Boyle) |
| Amount | £5,000 (GBP) |
| Funding ID | StrathWide 2023 Funding Call, University of Strathclyde |
| Organisation | University of Strathclyde |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 08/2023 |
| End | 08/2024 |
| Title | An end-to-end machine learning framework for the characterisation of tablet disintegration in real-time |
| Description | A combination of image segmentation and regime detection is used to extract and analyse data from the sessile drop experiment. The raw data is a video of the sessile drop experiment where a trained neural network is used to extract the water droplet and measure the surface area of the droplet. The surface area is then split into absorption and swelling using a sequence-to-sequence model. Models are then fitted to the absorption and swelling separately to learn more about these processes. This has been optimised to run in real-time on low-powered edge computing hardware but can also be run on more powerful hardware. |
| Type Of Material | Data analysis technique |
| Year Produced | 2023 |
| Provided To Others? | No |
| Impact | Allows for the efficient study of liquid absorption and swelling of large datasets of pharmaceutical tablets. Also, can run in real-time as part of an automated setup to provide information on absorption and swelling to the optimisation framework for uninterrupted tablet manufacturing. |
| Title | Crystallisation ontology for the generation of user interfaces and the collection of experimental data |
| Description | The project uses an ontological approach to develop software to collect data from crystallisation experiments, whether they achieve the desired result or not, to deliver a searchable database of factorial experiments for crystallisations. Consists of an ontology, a REST API and a user interface. |
| Type Of Material | Computer model/algorithm |
| Year Produced | 2024 |
| Provided To Others? | No |
| Impact | Researchers should be able to use the software to prevent the repeat of experiments that do not deliver the required end product. With a large enough dataset, searches may be able to provide optimisations to existing processes and it might be possible to use machine learning to suggest novel crystallisation techniques. |
| Title | DM2 Modelling and Optimisation Platform |
| Description | DM2 Modelling and Optimisation Platform includes a variety of data analysis techniques from statistical methods and analytical techniques to machine learning methodologies such as supervised and unsupervised learning. The optimisation methodologies consist of evolutionary algorithms for global search and Bayesian Optimisation for experiment recommendation. |
| Type Of Material | Data analysis technique |
| Year Produced | 2023 |
| Provided To Others? | No |
| Impact | The developed model-based optimisation frameworks will significantly reduce the time and materials required for the classic design of experiments. |
| Description | Collaboration with the ISCF Digital Design Accelerator Platform (DDAP) |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Project name: Digital Design Accelerator Project to Connect Active Material Design to Product Performance Provided models and data for the development of new tools on the project. Provided software development capacity via ARTICULAR RAs. |
| Collaborator Contribution | Data were provided to validate our AI models (large pharma: AZ, GSK, Pfizer). Partners provided end users to test our tools and interfaces. |
| Impact | New data analysis and handling capabilities that can work with data across pharmaceutical organisations |
| Start Year | 2019 |
| Description | Collaboration with the ISCF Digital Design Accelerator Platform (DDAP) |
| Organisation | GlaxoSmithKline (GSK) |
| Department | Research and Development GSK |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Project name: Digital Design Accelerator Project to Connect Active Material Design to Product Performance Provided models and data for the development of new tools on the project. Provided software development capacity via ARTICULAR RAs. |
| Collaborator Contribution | Data were provided to validate our AI models (large pharma: AZ, GSK, Pfizer). Partners provided end users to test our tools and interfaces. |
| Impact | New data analysis and handling capabilities that can work with data across pharmaceutical organisations |
| Start Year | 2019 |
| Description | Collaboration with the ISCF Digital Design Accelerator Platform (DDAP) |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Project name: Digital Design Accelerator Project to Connect Active Material Design to Product Performance Provided models and data for the development of new tools on the project. Provided software development capacity via ARTICULAR RAs. |
| Collaborator Contribution | Data were provided to validate our AI models (large pharma: AZ, GSK, Pfizer). Partners provided end users to test our tools and interfaces. |
| Impact | New data analysis and handling capabilities that can work with data across pharmaceutical organisations |
| Start Year | 2019 |
| Description | Project partnership with Altair |
| Organisation | Altair Engineering Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team is working with Altair to achieve the project outcomes. |
| Collaborator Contribution | Altair is working with the research team providing technical expertise and access to software to deliver towards the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Applied Materials (Perceptive Engineering) |
| Organisation | Applied Materials |
| Country | United States |
| Sector | Private |
| PI Contribution | The research team is working with Applied Materials to achieve the project outcomes. |
| Collaborator Contribution | Applied Materials is working with the research team providing technical expertise and access to software to deliver towards the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with AstraZeneca |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team is working with AstraZeneca to achieve the project outcomes. |
| Collaborator Contribution | AstraZeneca is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with BDD Pharma |
| Organisation | BDD Pharma Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team is working with BDD Pharma to achieve the project outcomes. |
| Collaborator Contribution | BDD Pharma is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Cambridge Crystallographic Data Centre (CCDC) |
| Organisation | Cambridge Crystallographic Data Centre |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The research team is working with CCDC to achieve the project outcomes. |
| Collaborator Contribution | CCDC is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Cancer Research UK |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The research team is working with Cancer Research UK to achieve the project outcomes. |
| Collaborator Contribution | Cancer Research UK is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Chiesi |
| Organisation | Chiesi |
| Country | Italy |
| Sector | Private |
| PI Contribution | The research team is working with Chiesi to achieve the project outcomes. |
| Collaborator Contribution | Chiesi is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Eli Lilly & Company |
| Organisation | Eli Lilly & Company Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The DM2 team is working with Eli Lilly & Company to achieve the project outcomes. |
| Collaborator Contribution | Eli Lilly & Company is working with the DM2 team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2022 |
| Description | Project partnership with GlaxoSmithKline (GSK) |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | The research team is working with GSK to achieve the project outcomes. |
| Collaborator Contribution | GSK is working with the research team and assisting/contributing to the project outcomes. Also, GSK is working with the DM2 platform 4 to contribute with a case study. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Henry Royce Institute |
| Organisation | Henry Royce Institute |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The DM2 team is working with Henry Royce Institute to achieve the project outcomes. |
| Collaborator Contribution | Henry Royce Institute is working with the DM2 team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with KUKA Robotics UK Ltd. |
| Organisation | KUKA Robotics |
| Department | KUKA Robotics UK Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team is working with KUKA Robotics to achieve the project outcomes. |
| Collaborator Contribution | KUKA Robotics is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Knowledge Transfer Network (KTN) |
| Organisation | Knowledge Transfer Network |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The DM2 team is working with KTN to achieve the project outcomes. |
| Collaborator Contribution | KTN is working with the DM2 team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Loughborough University |
| Organisation | Loughborough University |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Platform 3 of the DM2 project is led by Dr Brahim Benyahia, Loughborough University |
| Collaborator Contribution | Platform 3 of the DM2 project is led by Dr Brahim Benyahia, Loughborough University |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Malvern Panalytical |
| Organisation | Malvern Panalytical |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team is working with Malvern Panalytical to achieve the project outcomes. |
| Collaborator Contribution | Malvern Panalytical is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Medicines and Healthcare Regulatory Agency (MHRA) |
| Organisation | Medicines and Healthcare Regulatory Agency |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | The DM2 team is working with MHRA to achieve the project outcomes. |
| Collaborator Contribution | MHRA is working with the DM2 team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with NVIDIA |
| Organisation | NVIDIA |
| Country | Global |
| Sector | Private |
| PI Contribution | The research team is working with NVIDIA to achieve the project outcomes. |
| Collaborator Contribution | NVIDIA is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with National Physical Laboratory (NPL) |
| Organisation | National Physical Laboratory |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The research team is working with NPL to achieve the project outcomes. |
| Collaborator Contribution | NPL is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Pfizer |
| Organisation | Pfizer Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The DM2 team is working with Pfizer to achieve the project outcomes. |
| Collaborator Contribution | Pfizer is working with the DM2 team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2022 |
| Description | Project partnership with Process Systems Enterprise Limited (PSE)-Siemens |
| Organisation | Siemens Process Systems Engineering Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team is working with PSE to achieve the project outcomes. |
| Collaborator Contribution | PSE is working with the research team providing technical expertise and access to software to deliver towards the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Roche |
| Organisation | Roche Pharmaceuticals |
| Country | Global |
| Sector | Private |
| PI Contribution | The DM2 team is working with Roche to achieve the project outcomes. |
| Collaborator Contribution | Roche is working with the DM2 team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2022 |
| Description | Project partnership with Smith and Nephew (S&N) |
| Organisation | Smith and Nephew |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team is working with S&N to achieve the project outcomes. |
| Collaborator Contribution | S&N is working with the research team and assisting/contributing to the project outcomes. Also, S&N is working with the DM2 platform 4 to contribute with a case study. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with Takeda |
| Organisation | Takeda Pharmaceutical Company |
| Country | Japan |
| Sector | Private |
| PI Contribution | The DM2 team is working with Takeda to achieve the project outcomes. |
| Collaborator Contribution | Takeda is working with the DM2 team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2022 |
| Description | Project partnership with UCB Pharma |
| Organisation | UCB SA |
| Country | Belgium |
| Sector | Private |
| PI Contribution | The research team is working with UCB to achieve the project outcomes. |
| Collaborator Contribution | UCB is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with University of Cambridge |
| Organisation | University of Cambridge |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Platform 4 of the DM2 project is led by Dr Jagjit Singh Srai, University of Cambridge |
| Collaborator Contribution | Platform 4 of the DM2 project is led by Dr Jagjit Singh Srai, University of Cambridge |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with the Centre for Process Innovation (CPI) |
| Organisation | Centre for Process Innovation (CPI) |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team is working with CPI to achieve the project outcomes. |
| Collaborator Contribution | CPI is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with the University of Nottingham (Connected Everything) |
| Organisation | University of Nottingham |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The DM2 team is working with Connected Everything to achieve the project outcomes. |
| Collaborator Contribution | Connected Everything is working with the DM2 team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | Project partnership with the University of Strathclyde Centre for Process Analytics and Control Technology (CPACT) |
| Organisation | University of Strathclyde |
| Department | Centre for Process Analytics & Control Technology (CPACT) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The research team is working with CPACT to achieve the project outcomes. |
| Collaborator Contribution | CPACT is working with the research team and assisting/contributing to the project outcomes. |
| Impact | Made Smarter Innovation - Digital Medicines Manufacturing Research Centre |
| Start Year | 2021 |
| Description | SEARCH |
| Organisation | University of Strathclyde |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | New technology transfer to industry and academic partners |
| Collaborator Contribution | New applications e.g. in pharmaceutical manufacture, welding & joining, cladding |
| Impact | New project partnerships with end users - technology demonstrators |
| Start Year | 2021 |
| Description | Applied Materials software training workshop |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | A workshop for DM2 researchers to learn more about the functionality, capabilities and applications of the PE/AM software, PharmaMV. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Attending 11th pan-European Science Conference on QbD & PAT (EU PAT 11) conference, 12-13 October 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The 11th EuPAT conference brings together scientists and engineers from across academia, industry, and regulatory bodies to discuss the latest developments in the field of pharmaceutical process and product development. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://eupat.eufeps.org/ |
| Description | Attending a workshop on Machine Learning/Artificial Intelligence Workshop, Uni. of Strathclyde, Aug. 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Machine Learning/Artificial Intelligence Workshop, Uni. of Strathclyde, Aug. 2022, Glasgow, UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | Attending the Pharma Data & Digital Medicine, 11 September 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Pharma Data Congress - Showcasing success in digital transformation with FAIR, data infrastructure, architecture and data digitalisation & automation in the lab and computational approaches |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.rsc.org/events/detail/75804/pharma-data-and-digital-medicine-2023 |
| Description | CMAC/DM2 roadshow |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Event to promote CMAC atcivities including DM2 project with partners based in North America |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/events-database/us-roadshow |
| Description | DM2 Webinar: Machine learning for the development of medicines manufacturing (31 August 2023) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Webinar hosted by DM2 team to engage partners and prospective partners and interested stakeholders about our work in the area of machine learning. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/resource-database/dm-webinars-machine-learning |
| Description | DM2 Webinar: Robotic Innovations in Medicines Manufacturing (19 September 2023) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Webinar hosted by DM2 team to engage partners and prospective partners and interested stakeholders about our work in the area of robotics / cobotics. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/resource-database/dm2-webinars-robotic-innovations |
| Description | DM2 researchers training at MG2, June 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Two researchers from the DM2 recieved training on FlexaLab capsule filling machine at MG2, June 2022, Bologna, Italy. |
| Year(s) Of Engagement Activity | 2022 |
| Description | DM2 researchers training by Altair, Nov-Dec 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Training on Discrete Element Modelling using EDEM by Altair, Nov-Dec 2022, UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | DM2 researchers training by Siemens, during CMAC summer school programme, June 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Training on gproms by Siemens in CMAC summer school programme, June 2022, Crieff, UK |
| Year(s) Of Engagement Activity | 2022 |
| Description | DM2 training on augumented reality at CMAC summer school (12-16 June 2023) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | A week-long training programme that includes lectures and workshops. It will be attended by researchers and PhD students |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/news-database/cmac-summer-school-2023 |
| Description | DM² & Medelpharm Webinar: Self-driving Tableting DataFactory |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The webinar focused on how various technologies, like robotics, and instruments, such as Medelpharm's STYL'One Nano compaction simulator, are being brought together in customised formats to create this novel tablet development system and the benefits to be gained from employing it. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/resource-database/dm2-webinars-robotic-innovations-acn7l |
| Description | DM² Webinars: Digital Transformation in Medicine Manufacturing (28 June 2023) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Discuss the data related activities of DM2 and the importance of standardisation of data for ML, Ontologies and related AI. Guest industry presenter from project partner CCDC participating to give realworld application and share experience / learnings. Includes Q&A. Follow up, spin-off sessions planned. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/resource-database/dm-webinars-digital-transformation-in-medicines-manufacturing |
| Description | Doors Open Glasgow 2022 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | CMAC are participated in the #Glasgow Doors Open Days Festival (https://glasgowdoorsopendays.org.uk) Saturday 17th September 2022 (10am-4pm) at the Technology & Innovation Centre (TIC), University of Strathclyde. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://glasgowdoorsopendays.org.uk/building-no-booking/technology-innovation-centre-tic-university-... |
| Description | EPSRC 's Executive Chair, Lynn Gladden visit & blog mention |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | In a new blog post, the EPSRC 's Executive Chair, Lynn Gladden, reflects on her university visits, including a visit to CMAC at University of Strathclyde. It was a pleasure to host Lynn as part of this tour, showcasing our facilities and discussing how CMAC can work with UKRI to 'transform tomorrow together'. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://bit.ly/3Du7kgM |
| Description | Exhibited at the Digital Manufacturing Week, November 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Exhibited at the Digital Manufacturing Week. This event was brimming with expert content, and provided valuable peer to peer interaction and the best solutions available. It attracted over 6,000 manufacturers, industry leaders and technology solution providers. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://digital-manufacturing-week.com/ |
| Description | Future of Work in Medicines Manufacturing Round Table (interAct) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Round table discussion in collaboration with InterAct to gather views, opinions and insights from our networks to help shape future skills development activities |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/news-database/dm2-future-of-work-webinar |
| Description | Hosted visitors from Bristol Myers Squibb & Malvern Panalytical |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | CMAC were delighted to host visitors from Bristol Myers Squibb & Malvern Panalytical @newsfrom_MP 17th Aug 2022. Mike Tobyn (Senior Scientific Director at Bristol-Myers Squibb) gave an engaging seminar to the CMAC community titled Small Particles and Big Data. |
| Year(s) Of Engagement Activity | 2022 |
| Description | KTN Medicines Manufacturing round table discussion (25th May 2023) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Third sector organisations |
| Results and Impact | Colleagues from across the DM2 and wider CMAC leadership team sat with KTN Medicines Manufacturing Manager to disucss the soon to be launched Transforming Medicines Manufacturing Community of Practice, our involvement and further opportunities to collaborate for the benefit of the project. |
| Year(s) Of Engagement Activity | 2023 |
| Description | New CMAC Industry Board Chair - Dr Ivan Marziano |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | CMAC announced the new chair of the CMAC Industry Board by press release on the CMAC website and Twitter. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://cmac.ac.uk/news-database/a-new-chapter-for-cmacs-industry-board |
| Description | Official launch of the DM2 at the CMAC Open Days, May 2022 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The DM2 was officially launched at CMAC Open days. The event included exhibition of the DM2 platforms, partners, panel discussion, and keynote presentations. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://cmac.ac.uk/events-database/cmac-open-day-2022-hub-and-articular-showcase |
| Description | Organised a CMAC PhD Training Week Coding and ML Course, Sep. 2022/Mar. 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | CMAC PhD Training Week Coding and ML Course, Sep. 2022/Mar. 2023 |
| Year(s) Of Engagement Activity | 2022,2023 |
| URL | https://github.com/bionictoucan/cmac_coding_ml |
| Description | Organised a workshop on version control on GitLab, Jan 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Version control on GitLab, Jan 2023, Glasgow, UK |
| Year(s) Of Engagement Activity | 2023 |
| Description | Organised a workshop that focused on PharmaMV training, Jan 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | This workshop focused on providing a suitable training by Applied Materials experts on PharmaMV. DM2 and CMAC researchers have attended the training. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Organised the DM2 Data Platform workshop, Nov 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | This workshop was organised by the DM2 team to discuss the best ways to share and extract data related to medicines manufacturing. Different companies like CCDC and NVIDIA have attended. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Organising a webinar with Malvern Panalytical (From Particles to Drug Product Performance and Stability), March 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | About The Event How a pharmaceutical tablet disintegrates and dissolves when it comes in contact with a physiological fluid is crucial for the performance of the medicine. Critical performance characteristics are controlled by the chemical and physical properties of the drug substance and excipients paired with the manufacturing processes used to transform the powder into a compact. The microstructure created during manufacturing in combination with the wetting, swelling and dissolution properties of the raw materials are decisive for reliable drug release. Recently it has also become increasingly clearer that physical characteristics of pharmaceutical tablets change during storage, which in turn affect the performance when the medicine reaches the patient. In this webinar, we will discuss the interplay between particle properties, formulation, microstructure and stability-related performance changes. We will demonstrate the integrated use of advanced measurement techniques with multi-scale modelling approaches to gain insights into the relationship between particle characteristics, compact microstructure, storage conditions and the disintegration and dissolution performance of tablets. The new insights gained about the relationship between the raw material attributes, manufacturing process and drug product performance will allow us to move away from a laborious and lengthy empirical, trial and error, development to a digitally driven design process, where the tablet disintegrates and releases the drug substance in a reproducible and predictable manner. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://events.malvernpanalytical.com/W230321-DrugPerformance?_gl=1*jz6rit*_ga*MTYyNzg5ODI5OS4xNjc2N... |
| Description | Organising a webinar with Malvern Panalytical (Time to go digital: digitalization and AI in pharmaceutical R&D), Feb 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | About The Event CMAC's Digital Medicines Manufacturing research center (DM2) is a 3.5-year program co-funded by the Made Smarter Innovation at UK Research and Innovation. DM2 has ambitions to transform medicines development and manufacturing productivity, and drive a more patient-centric supply model, through digitalization. As a developer of laboratory technology, we at Malvern Panalytical see the value of digital transformation in materials science. Much of the data that is generated from our instrumentation does not end its journey in the lab. Rather, it is combined and harmonized with data from diverse sources to solve ever more complex challenges. For this reason, we join Prof. Blair Johnston in the DM2 center to learn and contribute to the integration of data pipelines and data science to improve medicines development. In this webinar, we will discuss the benefits to be gained from digitalization and the adoption of industrial digital technologies from a pharmaceutical perspective. We will also provide insights into the challenges of "going digital" and provide some examples of useful solutions and how we are implementing them across the DM2 Centre. These include technologies such as AI, digital twins, knowledge engineering as well as some practical solutions for bringing all staff within an organization along on the digital transformation journey. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://events.malvernpanalytical.com/W230228-DigitalManufacturing?_gl=1*uquwf0*_ga*MTYyNzg5ODI5OS4x... |
| Description | Organising the 11th pan-European Science Conference on QbD & PAT (EU PAT 11) conference workshop, 11 October 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The DM2 delivered a workshop on robotics and immersive technologies to a group of delegates from the pharma industry. |
| Year(s) Of Engagement Activity | 2023 |
| Description | Organising the Cambridge International Manufacturing Symposium, 21-22 September 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The annual Cambridge International Manufacturing Symposium is the chance to hear from world-leading business figures and thinkers on the challenges facing modern manufacturing. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.ifm.eng.cam.ac.uk/news/cambridge-international-manufacturing-symposium-2023/ |
| Description | Organising the ISIC conference (5-8 September 2023) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Research related conference to engage stakeholders and build network |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.isic2023.com/ |
| Description | Participated at Glasgow Explorathon event, Nov. 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Engaged with kids and families to explain the exciting research conducted at the DM2, such as medicines manufacturing and digitalisation, using simple experiments like marshmallow crystal builder, beat the machine game, and polymorphs of chocolate. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.explorathon.co.uk/ |
| Description | Participated at Knowledge Graph Forum by OnoText, Sep 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A 4-day hybrid event with a strong focus on industry applications presented by leading practitioners: Sep 26: Technology Ecosystem (virtually) Sep 27: Manufacturing, Aerospace, AECO (virtually) Sep 28: Life Sciences & Healthcare (live in Basel and virtually) Sep 29: Financial Services & Publishing (live in NYC and virtually) |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.ontotext.com/company/event/knowlege-graph-forum-2022/ |
| Description | Participated at MACH, April 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The DM2 engagement manager, Scott Hone, participated at MACH 2022, which is the national exhibition for inspiring, innovating and connecting engineering-based manufacturing. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.machexhibition.com/ |
| Description | Participation at CMAC Open Days, 14-16 November 2023 (Organiser) |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Research related conference to engage stakeholders and build network across CMAC research portfolio. Future CMAC Hub and aligned projects posters, showcases, lab tours and talks; DM2 demonstration of research progress to date and it's researchers present talks and posters. Some talks on the YouTube Channel: https://www.youtube.com/channel/UCbic3O4IH1TLMhExyY9Utmg. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/events-database/open-days-2023 |
| Description | Participation at InterAct Annual Conference, October 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The InterAct Network is a £4.4 million, Made Smarter Innovation funded, Economic and Social Research Council-led network that aims to bring together economic and social scientists, UK manufacturers, and digital technology providers to address the human issues resulting from the diffusion of new technologies in industry. The events aim are as follow: Gain actionable human insights into the future manufacturing environment. Network and build relationships with cross-sector experts interested in creating a positive, forward-thinking vision for UK industry. Build your narrative development skills to enhance the reach of you messaging in the digital environment. Take part in a collaborative workshop on the theme 'How do we create the digital manufacturing futures we want to see, together'. Engage with a panel of highly regarded speakers from the world of manufacturing, policy, and academia for an interactive Q&A session. Learn more about the InterAct Network, our future development and funding opportunities. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.madesmarter.uk/events/interact-annual-conference/ |
| Description | Participation at PharmaTech Integrates Conference, 21 September 2023 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Research related conference to engage stakeholders and build network |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.lifescienceintegrates.com/event/pharmatech-integrates-2023/ |
| Description | Participation at PharmaTech Integrates, September 2022 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Participation in the conference and visited the MMIC facility. Also, CMAC, who are based within the Technology and Innovation Centre, offered a tour of their world-class facilities. This provided an opportunity to meet with key researchers and to see the innovative technologies that are being developed, including the robotics they have integrated into the Digital CMC and data-factory stream. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.lifescienceintegrates.com/agenda/pharmatech-integrates-2022/ |
| Description | Participation at Pharmageddon, 18-19 Ocotber 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | 2-day innovation experience, designed to dismantle our assumptions about the status quo and recreate a better industry for patients, HCPs, and ourselves. You will collaborate with your peers and customers to take pharma apart, and build it back better. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.eucope.org/events/pharmageddon-event/ |
| Description | Participation at the Innovate UK Transforming Medicines Manufacturing Community of Practice - Launch Event, 4 Ocotber 2023 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Innovate UK Transforming Medicines Manufacturing Community of Practice - Launch Event |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://iuk.ktn-uk.org/events/transforming-medicines-manufacturing-community-of-practice-launch-even... |
| Description | Participation at the International Consortium for Advance Medicine Manufacturing (ICAMM), 27-28 April 2023 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The International Symposium of Continuous Manufacturing of Pharmaceutical (ISCMP) was established in 2012 and has organized three successful meetings bringing together leading scientist and technical experts from industry, academia, and global regulatory authorities. These symposia helped lay the foundation for future industry adoption and regulatory policies. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/events-database/icamm-2023 |
| Description | Participation at the Pharma Automation & Robotics Conference 2023 (20-21 April 2023) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | A Premier Meeting for Automation & Robotics R&D. DM2 Network & Skills rep attended on behalf of the project. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.pharmaceutical-tech.com/events/pharma-automation-robotics-2023 |
| Description | Participation at the RSC Science and the Parliament, 22 November 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Joined UKRI / EPSRC at their request to exhibit at this event held for MSPs and RSC members. Showcasing programmes funded and contribution to advancing science and developing skills of workers and future workers. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.rsc.org/events/detail/77031/science-and-the-parliament-2023 |
| Description | Queen's Anniversary Prize |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | CMAC were honoured to be part of the University of Strathclyde's team that received the Queen's Anniversary Prize for Higher and Further Education at St James's Palace on 23rd Feb 2022 for our excellence in Advanced Manufacturing. The university and CMAC have posted this on their websites. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://cmac.squarespace.com/news-database/qap |
| Description | Represented the DM2 in Robotics Industry Fair, Jan 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | A networking event for senior industry members with students at the University of Strathclyde to attend and showcase a more authentic manufacturing industry rather than a traditional careers fair. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.strathunion.com/events/6868/4083/ |
| Description | Roundtable discussion: Augmented Reality Skills Development for Medicines Manufacturing R&D (10 May 2023) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Round table with key project partners to gather insights on industry needs in this area to inform the DM2 skills development workpakage activities related to AR |
| Year(s) Of Engagement Activity | 2023 |
| Description | School Visit (Inverness) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Visit to local school as part of STEM week visiting 3 classes (75 children total) to discuss medicine manufacturing and conduct short experiments to engage children in the topic. |
| Year(s) Of Engagement Activity | 2023,2024 |
| Description | Scotland House Office Opens |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | CMAC are take up residence at Scotland House, London, UK on 29/04/2022. We're delighted to introduce the new CMAC Central London Office. Press release on website. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://cmac.ac.uk/news-database/cmac-london-office |
| Description | Scottish Secretary of State visit |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Policymakers/politicians |
| Results and Impact | CMAC were happy to show Scottish Secretary of State, Lord Offord of Garvel, around our world-leading facilities at the end of July 2022 as part of his broader visit to University of Strathclyde. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Showcased at Scotland Manufacturing and Supply Chain Conference, 25 October 2023 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Showcased the DM2 developed technologies and engaged with stakeholders |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.sdpscotland.co.uk/events/scotland-manufacturing-supply-chain-conference-exhibition-1505/ |
| Description | Showcased the DM2 1st generation demonstrator at CMAC Open Days, 14-16 November 2023 |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The team has been working hard throughout the year, driving forward the development of key industrial digital technologies (IDTs) for medicines manufacturing. This culminated in a showcase of our 1st-generation IDT demontrators at CMAC Open Days 2023. Read on to find out more about this, the other activities from throughout the year and what 2024 will bring. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://mailchi.mp/a641cbe2f8c3/dm2-newsletter-edition-5?e=ce5621b9fb |
| Description | Visit by MP Carol Monaghan |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Policymakers/politicians |
| Results and Impact | CMAC hosted MP Carol Monaghan on 5th October 2022 (@CMonaghanSNP) and showcased all the innovative medicines manufacturing research being carried out by CMAC here in Glasgow. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Visit by Parliamentary Under Secretary of State (Minister for Small Business, Consumers and Labour Markets) |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Policymakers/politicians |
| Results and Impact | 17/02/2022: CMAC host UK were thrilled to host Parliamentary Under Secretary of State (Minister for Small Business, Consumers and Labour Markets), @scullyp this week and provide a tour of our facilities highlighting #CMACs vision to transform #medicines development, manufacture and supply. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Visit by UK Science and Technology Select Committee |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Policymakers/politicians |
| Results and Impact | 11/02/2022: CMAC were delighted to host the UK Science and Technology Select Committee this week! We were excited to provide its members with a guided tour of our #facilities and show how #CMAC are helping tackle major UK and global challenges in #medicinesmanufacturing. #researchexcellence |
| Year(s) Of Engagement Activity | 2022 |
| Description | Webinar on the #FutureOfWork in Medicines #Manufacturing |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | @ESRC @InterActNetw0rk collaborated with CMAC to host a webinar on the #FutureOfWork in Medicines #Manufacturing, Thursday 12 January, 2023. Traget audience members: people manager or workplace stakeholder in the sector. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://linkedin.com/pulse/digital-medicines-manufacturing-future-work-webinar-lindsay-mcipd-/ |
| Description | Webinar: From particles to drug product performance and stability |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Webinar hosted by industry partner, Malvern Panalytical. Showcasing our medicines manufacturing related activities, the benefits of partnership and garnering opinion of our extended networks |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/resource-database/drug-performance-and-stability-webinar |
| Description | Webinar: Time to go digital: digitalisation and AI in pharmaceutical R&D |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Webinar hosted by industry partner, Malvern Panalytical. Showcasing our data related activities, the benefits of partnership and garnering opinion of our extended networks |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://cmac.ac.uk/events-database/future-of-work-webinar-cp9c2 |